WY-14643,一种针对GPIbα受体的新型抗血小板和抗血栓剂
Chen Cao1, Qingyuan Yang2, Xiaoshuang Xia1
1Department of Neurology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China.
Thrombosis research
|April 26, 2024
概括
皮里尼西克酸 (WY-14643) 抑制了血小板聚合,并作为一种糖蛋白IBα (GPIbα) 抗剂. 这种降脂药物显示出作为动脉样硬化疾病的抗血小板剂的潜力,而不会增加出血风险.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管研究研究心血管研究
- 血栓形成的原因之一是血栓形成.
背景情况:
- 动脉样硬化疾病包括低脂血症和血小板激活.
- 皮里尼西克酸 (WY-14643) 是一种已知的降脂药物.
- 这项研究研究了其抗血小板和抗血栓机制.
研究的目的:
- 评估WY-14643.3的抗血小板和抗血栓作用.
- 为了阐明WY-14643抗血小板作用的潜在机制.
- 评估其在动脉样硬化疾病中的治疗潜力.
主要方法:
- 评估血小板聚合,凝块收缩和使用光聚合计扩散.
- 利用PPARα淘汰血小板来识别药物的目标.
- 采用CETSA,SPR和分子对接来研究WY-14643与GPIbα的相互作用.
- 在小鼠中腔动脉血栓形成模型和小鼠尾部出血模型中的出血中研究了抗血栓作用.
主要成果:
- WY-14643证明了血小板聚合,凝块收缩和扩散的度依赖抑制.
- 该药物直接与糖蛋白Iba (GPIbα) 相互作用,作为一个对抗剂.
- WY-14643抑制了血栓诱导的信号通路,并在体内显示出抗血栓作用,而不会增加出血.
结论:
- WY-14643既可以作为PPARα激动剂,也可以作为GPIbα对抗剂.
- 它表现出显著的抗血小板和抗血栓性质.
- 由于其双重的降脂和抗血小板作用,而没有出血并发症,WY-14643可能比目前的动脉硬性血栓形成的抗血小板疗法具有优势.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
169
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
169
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
687
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
687
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
741
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
741
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K